Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
The French government, sole shareholder of state-owned IN Groupe, backed IN Groupe's acquisition of IDEMIA Smart Identity (ISI) with a capital increase, completed 2025-07-01. The deal — IN Groupe's largest since its creation, with press estimates as high as EUR 1 billion though terms were not officially disclosed — creates a combined entity with over 4,000 employees and consolidated turnover above EUR 1 billion, making IN Groupe the world's largest provider of physical/digital identity cards and second-largest passport provider. The Ministry framed the operation as building a "global champion" in identity documents to secure French/ European sovereignty over the identity and biometrics value chain.
Bpifrance, France's state-owned public investment bank, took a 1.8% equity stake with board representation in Opella — the Sanofi-spun-off consumer healthcare unit that makes Doliprane (paracetamol) and other OTC brands — as part of the closing of Sanofi's sale of a 50% controlling stake to US private equity firm Clayton, Dubilier & Rice (CD&R). Sanofi retains 48.2%. The stake was widely read domestically as a state sovereignty guarantee attached to a politically contentious foreign takeover of a company regarded as critical to French medicine supply security.